{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:19:53Z","timestamp":1760782793455},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"S1","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Metastatic bone disease affects many cancer patients and has a significant disease burden because of complications such as pathologic fractures and severe pain, which affect patient mobility and quality of life. Bisphosphonates are the current standard of care for treating metastatic bone disease. Available agents have shown varying degrees of efficacy in clinical trials, and treatment potential can be limited by efficacy, tolerance, or toxicity issues. Ibandronate (Bondronat\u00ae; F. Hoffman-La Roche Ltd., Basel, Switzerland, http:\/\/www.roche.com) is a highly potent, single-nitrogen bisphosphonate that is available in i.v. and oral formulations. In phase III trials in breast cancer patients, both formulations reduced the incidence of skeletal complications associated with metastatic bone disease and had significant and sustained effects on bone pain and patient quality of life. Open-label studies of loading-dose ibandronate administered over consecutive days suggest it also may be useful for relieving severe or opioid-resistant metastatic bone pain. New trials have been designed or are in progress that may extend the clinical indications of ibandronate for patients with metastatic bone disease.<\/jats:p>","DOI":"10.1634\/theoncologist.10-90001-8","type":"journal-article","created":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T20:42:55Z","timestamp":1130877775000},"page":"8-13","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data"],"prefix":"10.1093","volume":"10","author":[{"given":"Richard","family":"Bell","sequence":"first","affiliation":[{"name":"The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,10,1]]},"reference":[{"key":"2021122209520110300_R1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122209520110300_R2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"2021122209520110300_R3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/107327480200900605","article-title":"The use of bisphosphonates in patients with breast cancer","volume":"9","author":"Poznak","year":"2002","journal-title":"Cancer Control"},{"key":"2021122209520110300_R4","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122209520110300_R5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209520110300_R6","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122209520110300_R7","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00002018-200326090-00005","article-title":"Extended safety profile of oral clodronate after long-term use in primary breast cancer patients","volume":"26","author":"Atula","year":"2003","journal-title":"Drug Saf"},{"issue":"suppl 4","key":"2021122209520110300_R8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209520110300_R9","doi-asserted-by":"crossref","first-page":"CD003474","DOI":"10.1002\/14651858.CD003474","article-title":"Bisphosphonates for breast cancer","volume-title":"Cochrane Database Syst Rev","author":"Pavlakis","year":"2002"},{"key":"2021122209520110300_R10","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multi-center, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209520110300_R11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122209520110300_R12","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122209520110300_R13","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209520110300_R14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"The Oncologist"},{"key":"2021122209520110300_R15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"2021122209520110300_R16","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122209520110300_R17","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209520110300_R18","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122209520110300_R19","volume-title":"Zometa\u00ae (zoledronic acid). US summary of product characteristics","author":"Novartis Pharmaceuticals Corporation","year":"2004"},{"key":"2021122209520110300_R20","volume-title":"Zometa\u00ae (zoledronic acid). EU summary of product characteristics","author":"Novartis International AG","year":"2005"},{"key":"2021122209520110300_R21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2003.10.003","article-title":"Pain management in cancer patients with bone metastases remains a challenge","volume":"27","author":"Yau","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"suppl 3","key":"2021122209520110300_R22","first-page":"iii50","article-title":"Treatment of painful bone metastases in Europe and Canada: the role of bisphosphonates","volume":"15","author":"McPartland","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"2021122209520110300_R23","first-page":"iii224","article-title":"Use of bisphosphonates for the palliative care of metastatic bone pain: US market research results","volume":"15","author":"Johnson","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122209520110300_R24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0360-3016(99)00276-X","article-title":"Cancer pain management by radio-therapists: a survey of Radiation Therapy Oncology Group physicians","volume":"47","author":"Cleeland","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122209520110300_R25","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (corrigendum published in Ann Oncol 2004;15:180)","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122209520110300_R26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"2021122209520110300_R27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"2021122209520110300_R28","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2004.03.025","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel","year":"2004","journal-title":"Eur J Cancer"},{"key":"2021122209520110300_R29","first-page":"46","article-title":"Risk reductions in metastatic breast cancer: multivariate Poisson regression analyses of oral and i.v. ibandronate","volume":"22","author":"Body","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122209520110300_R30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ejcsup.2004.01.002","article-title":"Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease","author":"Body","year":"2004","journal-title":"Eur J Cancer"},{"issue":"suppl 3","key":"2021122209520110300_R31","first-page":"iii225","article-title":"Ibandronate is effective in preventing skeletal events in patients with bone metastases secondary to breast and colorectal cancer","volume":"15","author":"Heras","year":"2004","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"2021122209520110300_R32","first-page":"12S","article-title":"Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption in patients with breast cancer and bone metastases: results from a comparative phase III trial","volume":"23","author":"Body","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209520110300_R33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"key":"2021122209520110300_R34","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1046\/j.0902-4441.2003.132_1.x","article-title":"Is ibandronate effective in multiple myeloma? [letter]","volume":"71","author":"Body","year":"2003","journal-title":"Eur J Haematol"},{"key":"2021122209520110300_R35","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2021122209520110300_R36","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S1359-6349(03)90923-2","article-title":"High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer","author":"Heidenreich","year":"2003","journal-title":"Eur J Cancer"},{"key":"2021122209520110300_R37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2021122209520110300_R38","first-page":"396","article-title":"Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer","volume":"11","author":"Ohlmann","year":"2003","journal-title":"Support Care Cancer"},{"key":"2021122209520110300_R39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2021122209520110300_R40","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2021122209520110300_R41","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q","article-title":"A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.10-90001-8","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.10-90001-8","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/S1\/8\/41852394\/oncolo_10_s1_8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/10\/S1\/8\/41852394\/oncolo_10_s1_8.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:45:53Z","timestamp":1640195153000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/10\/S1\/8\/6387345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10,1]]},"references-count":41,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2005,10,1]]},"published-print":{"date-parts":[[2005,10,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.10-90001-8","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,10,1]]},"published":{"date-parts":[[2005,10,1]]}}}